Genetic and epigenetic similarities and differences between childhood and adult AML

Pediatric Blood and Cancer

Volumn 58, Issue 4, 2012, Pages 525-531

  Juhl Christensen, Caroline ^a   Ommen, Hans Beier ^a   Aggerholm, Anni ^a   Lausen, Birgitte ^b   Kjeldsen, Eigil ^a   Hasle, Henrik ^a   Hokland, Peter ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

Acute myeloid leukemia; AML; Gene mutation; Molecular diagnostics and therapy; Molecular genetics; Promoter hypermethylation

Indexed keywords

CORE BINDING FACTOR; FLT3 LIGAND; MULTIDRUG RESISTANCE PROTEIN 1; NUCLEOPHOSMIN; PROTEIN P15; UVOMORULIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; DNA METHYLATION; EXON; FEMALE; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN CELL; INFANT; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROMOTER REGION; SCHOOL CHILD; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, MYELOID, ACUTE; MALE; NEOPLASM PROTEINS; PROMOTER REGIONS, GENETIC;

EID: 84856860527     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23397     Document Type: Article

References (42)

1. Swerdlow S, Campo E, Harris N, et al., editors. WHO Classification of tumours of haematopoietic and lymphoid tissues. Geneva, Switzerland: IARC Press; 2008.
2. Esteller M. Profiling aberrant DNA methylation in hematologic neoplasms: A view from the tip of the iceberg. Clin Immunol 2003; 109: 80-88.
3. Raimondi SC, Chang MN, Ravindranath Y, et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: Clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood 1999; 94: 3707-3716.
4. Lie SO, Abrahamsson J, Clausen N, et al. Long-term results in children with AML: NOPHO-AML Study Group-Report of three consecutive trials. Leukemia 2005; 19: 2090-2100.
5. Meshinchi S, Alonzo TA, Stirewalt DL, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood 2006; 108: 3654-3661.
6. Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008; 111: 2776-2784.
7. Liang DC, Shih LY, Huang CF, et al. CEBPalpha mutations in childhood acute myeloid leukemia. Leukemia 2005; 19: 410-414.
8. Hollink IH, van den Heuvel-Eibrink MM, Zimmermann M, et al. Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood 2009; 113: 5951-5960.
9. Wong IHN, Ng MHL, Huang DP, et al. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: Potential prognostic implications. Blood 2000; 95: 1942-1949.
10. Tsellou E, Troungos C, Moschovi M, et al. Hypermethylation of CpG islands in the promoter region of the p15INK4B gene in childhood acute leukaemia. Eur J Cancer 2005; 41: 584-589.
11. Hasegawa D, Manabe A, Kubota T, et al. Methylation status of the p15 and p16 genes in paediatric myelodysplastic syndrome and juvenile myelomonocytic leukaemia. Br J Haematol 2005; 128: 805-812.
12. Vidal DO, Paixao VA, Brait M, et al. Aberrant methylation in pediatric myelodysplastic syndrome. Leuk Res 2007; 31: 175-181.
13. Abrahamsson J, Forestier E, Heldrup J, et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol 2011; 29: 310-315.
14. Yunis JJ. New chromosome techniques in the study of human neoplasia. Hum Pathol 1981; 12: 540-549.
15. Olesen LH, Aggerholm A, Andersen BL, et al. Molecular typing of adult acute myeloid leukaemia: Significance of translocations, tandem duplications, methylation, and selective gene expression profiling. Br J Haematol 2005; 131: 457-467.
16. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1, 612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 2322-2333.
17. Lie SO, Abrahamsson J, Clausen N, et al. Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: Results of NOPHO-AML trials. Br J Haematol 2003; 122: 217-225.
18. Virappane P, Gale R, Hills R, et al. Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: The United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2008; 26: 5429-5435.
19. Toyota M, Kopecky KJ, Toyota M, et al. Methylation profiling in acute myeloid leukemia. Blood 2001; 97: 2823-2829.
20. Shimamoto T, Ohyashiki JH, Ohyashiki K. Methylation of p15INK4b and E-cadherin genes is independently correlated with poor prognosis in acute myeloid leukemia. Leuk Res 2005; 29: 653-659.
21. Rethmeier A, Aggerholm A, Olesen LH, et al. Promoter hypermethylation of the retinoic acid receptor beta2 gene is frequent in acute myeloid leukaemia and associated with the presence of CBFbeta-MYH11 fusion transcripts. Br J Haematol 2006; 133: 276-283.
22. Aggerholm A, Holm MS, Guldberg P, et al. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol 2006; 76: 23-32.
23. Murphy KM, Levis M, Hafez MJ, et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn 2003; 5: 96-102.
24. Dohner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations. Blood 2005; 106: 3740-3746.
25. Juhl-Christensen C, Bomberg M, Melsvik D, et al. Capillary gel electrophoresis: A simple method for identification of mutations and polymorphisms in the CEBPA gene in patients with acute myeloid leukaemia. Eur J Haematol 2008; 81: 273-280.
26. Summers K, Stevens J, Kakkas I, et al. Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia 2007; 21: 550-551, author reply 552.
27. Boyd VL, Zon G. Bisulfite conversion of genomic DNA for methylation analysis: Protocol simplification with higher recovery applicable to limited samples and increased throughput. Anal Biochem 2004; 326: 278-280.
28. Worm J, Aggerholm A, Guldberg P. In-tube DNA methylation profiling by fluorescence melting curve analysis. Clin Chem 2001; 47: 1183-1189.
29. Ostgard LS, Kjeldsen E, Holm MS, et al. Reasons for treating secondary AML as de novo AML. Eur J Haematol 2010; 85: 217-226.
30. Frankfurt O, Licht JD, Tallman MS. Molecular characterization of acute myeloid leukemia and its impact on treatment. Curr Opin Oncol 2007; 19: 635-649.
31. Harrison CJ, Hills RK, Moorman AV, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12. J Clin Oncol 2010; 28: 2674-2681.
32. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326-4335.
33. Chou WC, Tang JL, Lin LI, et al. Nucleophosmin mutations in de novo acute myeloid leukemia: The age-dependent incidences and the stability during disease evolution. Cancer Res 2006; 66: 3310-3316.
34. Cazzaniga G, Dell'Oro MG, Mecucci C, et al. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood 2005; 106: 1419-1422.
35. Thiede C, Creutzig E, Reinhardt D, et al. Different types of NPM1 mutations in children and adults: Evidence for an effect of patient age on the prevalence of the TCTG-tandem duplication in NPM1-exon 12. Leukemia 2007; 21: 366-367.
36. Brown P, McIntyre E, Rau R, et al. The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood 2007; 110: 979-985.
37. Mikeska T, Candiloro ILM, Dobrovic A. The implications of heterogeneous DNA methylation for the accurate quantification of methylation. Epigenomics 2010; 2: 561-573.
38. Aggerholm A, Guldberg P, Hokland M, et al. Extensive intra- and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia. Cancer Res 1999; 59: 436-441.
39. Li Q, Kopecky KJ, Mohan A, et al. Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia. Clin Cancer Res 1999; 5: 1077-1084.
40. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999; 21: 163-167.
41. Esteller M, Corn PG, Baylin SB, et al. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61: 3225-3229.
42. Issa J. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004; 4: 988-993.